<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

PDX Mouse Clinical Trials

Translational Models, Predictive Biomarkers, New Indications, Deeper Drug Insights

The Challenge: Enhancing Clinical Translation in Oncology Drug Development

Many oncology therapies fail in clinical trials—especially in Phase II—due to a lack of efficacy. This underscores the need for more predictive preclinical models that better mirror human responses and improve clinical trial success rates.

Our Solution: PDX Mouse Clinical Trials (MCTs)

(Previously known as HuTrial)

Patient-Derived Xenograft (PDX) Models are transforming preclinical oncology research by offering more clinically relevant data. By preserving the key features of patient tumors, PDX models provide a powerful tool for drug development and clinical translation. These models help bridge the gap between preclinical studies and clinical success, offering oncology drug developers a reliable pathway to more accurate predictions and outcomes.

Request a Quote

HuBase™: The World’s Largest Collection of Clinically Relevant PDX Models

Access 2,500+ global PDX models. Tailor your selections based on indication, drug responses, patient histories, and multiomics data for precision in your studies.

Access database

Figure. A representative PDX Mouse Clinical Trial DesignFigure. A representative PDX Mouse Clinical Trial Design

Why Choose PDX Mouse Clinical Trials?

Enhancing Oncology Drug Development with Predictive Models

PDX Mouse Clinical Trials offer a unique advantage for oncology drug developers by providing:

  • Better Clinical Translation: PDX models closely mimic human tumor biology, maintaining key features such as the genetic and phenotypic characteristics of patient tumors, leading to more accurate predictions of clinical outcomes.
  • Predictive Biomarker Discovery: These models help identify biomarkers for patient stratification, enabling more personalized treatment strategies and increasing the likelihood of clinical trial success.
  • Exploration of New Indications: PDX models allow for the evaluation of therapies across diverse tumor types, uncovering potential new therapeutic applications and expanding indications.
  • Deeper Drug Response Insights: Gain a deeper understanding of drug efficacy, mechanisms of action (MoA), and resistance mechanisms. PDX models are invaluable for optimizing drug combinations and reducing attrition in clinical development.

Why Choose Crown Bioscience for PDX Mouse Clinical Trials?

The PDX Expert:

  • Largest Commercial PDX Collection and Quality
    • Better representation of patient populations
    • > 500 live PDX models for fast track service
    • Patented NGS QC Method ensures the highest PDX model quality
  • Accurate Biomarker Assay & Data Interpretation
    • Our specialized methodologies ensure precise biomarker analysis, even with complex mixed tumor tissues in PDXs1-3

MCT Data Science Expert Support:

  • Bioinformatics Expertise
    • Expert design of optimized, cost-efficient, data-driven MCTs4
  • Tailored Bioinformatics Consultation
    • Receive biostatistical and bioinformatics support, including model selection and study design consultation.
  • End-to-End Service
    • Complete support from trial design to data analysis, ensuring seamless execution
Crown Bioscience for PDX Mouse Clinical Trials Fig. End-to-end MCT Data Science Expert Support
Request a quote

Rely on the Experts for Accurate PDX Biomarker Insights

PDX models are among the most predictive of patient tumors, but they come with unique challenges. After human tumor fragments are engrafted into immunodeficient mice, human stroma is quickly replaced by mouse cells, including immune components and blood vessels. This can complicate biomarker analysis and data interpretation, potentially leading to misleading results if human and mouse signals aren’t properly distinguished1,2.

With our deep expertise and a proven track record of publications1-3, Crown Bioscience leads the field in overcoming these challenges, delivering reliable, actionable insights that drive successful oncology research.

Xenografts
BLOG

Are You Doing Proteomics Correctly for Xenografts?

Read Now

Delivering Comprehensive Solutions in PDX Mouse Clinical Trials

Our PDX Mouse Clinical Trials are designed to maximize the impact of your oncology research by offering:

  • Optimized Clinical Trial Designs: Tailored to maximize predictive power and ensure clinical relevance, setting your studies up for success in oncology drug development.
  • Integrated Data Reports: Our comprehensive reports combine biomarker discovery, PK/PD analysis, and bioinformatics to provide a holistic view of your study's outcomes.
  • Seamless Service: From trial initiation to final report, our dedicated team ensures consistency, quality, and efficiency at every stage, empowering you to confidently advance in your drug development journey.
Step by Step Guide for Mouse Clinical TrialFigure. Step by Step Guide for Mouse Clinical Trial

Applications of PDX Mouse Clinical Trials in Oncology

PDX Mouse Clinical Trials support diverse oncology research areas, helping to drive better clinical translation and drug development outcomes:

  • Biomarker Discovery & Validation: Identify biomarkers for personalized treatment strategies, improving patient stratification and increasing clinical trial success.
  • Clinical Stratification: Generate precise data to support targeted therapies, improving patient selection and enhancing treatment efficacy.
  • Exploring New Indications: Investigate therapies across various cancer types, discovering new therapeutic uses and expanding treatment possibilities.
  • Targeted Research: Focus on specific genetic mutations or cancer drivers to refine therapeutic approaches and advance precision medicine.
  • Drug Combination Strategies: Evaluate drug combinations to overcome resistance and optimize treatment responses, backed by our innovative in vivo synergy assessments for enhanced 

Contact Us
Your privacy is important to us. We'll never share your information.

Related Services

Preclinical Biomarker Discovery

Preclinical Biomarker Discovery

Learn more

Laboratory Services

Laboratory Services

Biomarker analysis and Bioanalysis

Learn more

tma

Tumor Tissue Microarray

Screen hundreds of tumor samples at a time for biomarkers of interest

Learn more

PKPD-Toxicity Services

PK/PD-Toxicity Services 

Learn more

Related Resources

WhitePaper1

White Paper

The Ultimate Guide to PDX Mouse Clinical Trials

download now

WhitePaper2

White Paper

How to Optimize Mouse Clinical Trials Through Statistical Endpoints and Study Design

download now

odw-preclinical-response

Webinar

Predicting Clinical Response with Mouse Clinical Trials

watch now

pdx-mct

Factsheet

PDX Mouse Clinical Trial

download now

odw-thumb

On Demand Webinar

Mouse Clinical Trials: The Power Behind Study Design

Watch Now

References

1. Wubin Qian, Xiaobo Chen, Yanghui Sheng, Likun Zhang, Jingjing Wang, Zhenzhen Song, Qi-Xiang Li, Sheng Guo; Tumor Purity in Preclinical Mouse Tumor Models. Cancer Research Communications 2 May 2022; 2 (5): 353–365. https://doi.org/10.1158/2767-9764.CRC-21-0126

2. Zhaomei Shi, Binchen Mao, Xiaobo Chen, Piliang Hao, Sheng Guo; Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models. Cancer Research Communications 1 February 2023; 3 (2): 202–214. https://doi.org/10.1158/2767-9764.CRC-22-0431

3. Huajun Zhou, Binchen Mao, Sheng Guo; Mathematical Modeling of Tumor Growth in Preclinical Mouse Models with Applications in Biomarker Discovery and Drug Mechanism Studies. Cancer Research Communications 2024; https://doi.org/10.1158/2767-9764.CRC-24-0059

4. Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li. The design, analysis and application of mouse clinical trials in oncology drug development. BMC Cancer 19, 718 (2019). https://doi.org/10.1186/s12885-019-5907-7

5. Binchen Mao, Sheng Guo; Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models. Cancer Research Communications 2 October 2023; 3 (10): 2146–2157. https://doi.org/10.1158/2767-9764.CRC-23-0243